Stage IIIB or IV NSCLC with progression as per RECIST v1.1 after 2 or more cycles of platinum-doublet chemotherapy; PD-L1 TPS ≥ 1%; aged ≥ 18; ECOG PS of 0 or 1. Here, CD274 is linked to non-small cell lung carcinoma.